PTX3 and C1QA

Number of citations of the paper that reports this interaction (PubMedID 12645945)
76

Data Source:
HPRD (in vitro, in vivo)

		PTX3	C1QA
Description		pentraxin 3	complement C1q A chain
Image		No pdb structure
GO Annotations	Cellular Component	Extracellular Region Extracellular Space Extracellular Matrix Specific Granule Lumen Tertiary Granule Lumen	Extracellular Region Collagen Trimer Complement Component C1 Complex Cell Synapse Collagen-containing Extracellular Matrix Postsynapse
	Molecular Function	Complement Component C1q Binding (1->3)-beta-D-glucan Binding Protein Binding Identical Protein Binding Virion Binding	Amyloid-beta Binding Protein Binding
	Biological Process	Ovarian Cumulus Expansion Response To Yeast Inflammatory Response Opsonization Extracellular Matrix Organization Neutrophil Degranulation Negative Regulation By Host Of Viral Process Negative Regulation By Host Of Viral Exo-alpha-sialidase Activity Negative Regulation By Host Of Viral Glycoprotein Metabolic Process Innate Immune Response Positive Regulation Of Nitric Oxide Biosynthetic Process Negative Regulation Of Viral Entry Into Host Cell Positive Regulation Of Phagocytosis Negative Regulation Of Exo-alpha-sialidase Activity Negative Regulation Of Glycoprotein Metabolic Process	Microglial Cell Activation Complement Activation Complement Activation, Classical Pathway Cell-cell Signaling Aging Response To Iron Ion Viral Process Neuron Remodeling Regulation Of Complement Activation Innate Immune Response Astrocyte Activation Synapse Organization Synapse Pruning Complement-mediated Synapse Pruning Vertebrate Eye-specific Patterning Positive Regulation Of Neuron Death
Pathways		Neutrophil degranulation	Initial triggering of complement Classical antibody-mediated complement activation Regulation of Complement cascade
Drugs			Cetuximab Etanercept Adalimumab Abciximab Gemtuzumab ozogamicin Trastuzumab Rituximab Basiliximab Muromonab Ibritumomab tiuxetan Tositumomab Alemtuzumab Alefacept Efalizumab Natalizumab Palivizumab Daclizumab Bevacizumab
Diseases			Classic complement pathway component defects, including the following eight diseases: C1q alpha-chain deficiency; C1q beta-chain deficiency; C1q gamma-chain deficiency; C1r deficiency; C1s deficiency; C2 deficiency; C3 deficiency; C4 deficiency
GWAS		Body mass index ( 26426971)
Interacting Genes		15 interacting genes: C1QA C1QB C1QC CFH FGF1 FGF16 FGF17 FGF18 FGF2 FGF20 FGF22 FGF5 FGF7 FGF8 MTNR1A	28 interacting genes: APCS BAG6 C1QB C1QBP C1QC C1R C1S CD93 COL2A1 CR1 CRP CSPG4 DCN FN1 GNPNAT1 HIPK3 HRG HSPB2 NLGN3 PIAS2 PPP1CA PPP1CC PTX3 RHOA SGTA SLC25A47 UBQLN1 UBQLN2
Entrez ID		5806	712
HPRD ID		03928	00393
Ensembl ID		ENSG00000163661	ENSG00000173372
Uniprot IDs		P26022	A0A024RAG6 P02745
PDB IDs			1PK6 2JG8 2JG9 2WNU 2WNV 5HKJ 5HZF 6FCZ
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?